Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non– Small-Cell Lung Cancer Patients  Ryota Nakamura, MD, Yoshihisa Inage,

Published byMaija Auvinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non– Small-Cell Lung Cancer Patients  Ryota Nakamura, MD, Yoshihisa Inage,"— Presentation transcript:

1 Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non– Small-Cell Lung Cancer Patients  Ryota Nakamura, MD, Yoshihisa Inage, MD, PhD, Rika Tobita, MD, Kazuko Mori, MD, PhD, Takeshi Numata, MD, Hidetoshi Yanai, MD, Takeo Endo, MD, PhD, Haruo Ohtani, MD, PhD, Hiroaki Satoh, MD, PhD, Kenji Yuzawa, MD, PhD, Masanori Koizumi, MD, PhD, Hamaichi Ueki, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 9, Pages (September 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Modified Schwartz equation of tumor volume. a = maximum tumor diameter; b = largest perpendicular tumor diameter; t = interval between 2 CT scans; V 0 = tumor volume at the initial CT scan; V t = tumor volume at preoperative CT scan. CT, computed tomography; VDT, volume doubling time. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non– Small-Cell Lung Cancer Patients  Ryota Nakamura, MD, Yoshihisa Inage,"

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Brett W. Carter, MD, Edith M. Marom, MD, Frank C. Detterbeck, MD 

Brett W. Carter, MD, Edith M. Marom, MD, Frank C. Detterbeck, MD 
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,
The Moth-Eaten Lung Journal of Thoracic Oncology

The Moth-Eaten Lung Journal of Thoracic Oncology
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Similar presentations

Ads by Google